Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219215 | 0.71 | — | — | |
| SCHEMBL7100438 | 0.70 | PIK3CG (0.37) | PIK3CG | |
| SCHEMBL3292267 | 0.69 | PIK3CG (0.47) | PIK3CG | |
| SCHEMBL1378685 | 0.67 | PIK3CG (0.46) | PIK3CG | |
| SCHEMBL30290978 | 0.60 | PIK3CG (0.41) | PIK3CG | |
| SCHEMBL30611771 | 0.60 | PIK3CG (0.41) | PIK3CG | |
| SCHEMBL2490862 | 0.60 | PIK3CG (0.41) | PIK3CG | |
| SCHEMBL21331740 | 0.59 | EGFR (0.33) | — | |
| SCHEMBL30124132 | 0.59 | EGFR (0.54) | PIK3CG | |
| SCHEMBL35632 | 0.59 | EGFR (0.54) | PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045496-B2 | N-substituted oxazinopteridines and oxazinopteridinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-02 | — | — | US | disclosed |
| US-9045496-B2 | N-substituted oxazinopteridines and oxazinopteridinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-02 | — | — | US | disclosed |
| EP-2678342-B1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-20140309219-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2014-10-16 | — | — | US | disclosed |
| US-8791107-B2 | N-substituted oxazinopteridines and oxazinopteridinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8791107-B2 | N-substituted oxazinopteridines and oxazinopteridinones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-29 | — | — | US | disclosed |
| EP-2678342-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | Takeda Pharmaceutical Company Limited (JP) | 2014-01-01 | — | — | EP | disclosed |
| CN-103384672-A | N-substituted oxazinopteridines and oxazinopteridinones | TAKAEDA CHEMICAL IND LTD | 2013-11-06 | — | — | CN | disclosed |
| WO-2012148548-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-01 | — | — | WO | disclosed |
| US-20120220575-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309219-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | PIK3CD, PIK3CA, AKT2 | PIK3CG 10/4885 |
| US-20120220575-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | PIK3CD, PIK3CA, AKT2 | PIK3CG 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.